Initial treatment of COPD with LABA-ICS or LABA-LAMA: real-world comparative effectiveness.

ABSTRACT:

Background

The 2023 Global initiative for chronic Obstructive Lung Disease (GOLD) recommendations advocate long-acting beta₂ agonist (LABA) and long-acting muscarinic antagonist (LAMA) combinations (LABA-LAMA) for the initial pharmacological treatment of patients with chronic obstructive pulmonary disease (COPD) with multiple exacerbations. However, this choice, rather than combinations of LABA and inhaled corticosteroids (LABA-ICS), no longer recommended in GOLD, was based on randomised trials that excluded patients with multiple prior exacerbations.

Research question

What is the comparative effectiveness of initiating COPD treatment with LABA-ICS versus LABA-LAMA inhalers, particularly in patients with multiple COPD exacerbations, in a real-world clinical practi

SUBMITTER: Suissa S 

PROVIDER: S-EPMC12716541 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature